Literature DB >> 20052748

Phase1/-2 study of Pomalidomide in myelofibrosis.

Ruben A Mesa, Animesh D Pardanani, Kebede Hussein, Wenting Wu, Susan Schwager, Mark R Litzow, William J Hogan, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20052748     DOI： 10.1002/ajh.21598

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  33 in total

Review 1.  Future therapies for the myeloproliferative neoplasms.

Authors:  Robyn Scherber; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

Review 2.  Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.

Authors:  Giovanni Barosi; Letizia Lupo; Vittorio Rosti
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 3.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

4.  Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Authors:  Han W Tun; Patrick B Johnston; Lisa M DeAngelis; Pamela J Atherton; Levi D Pederson; Patricia A Koenig; Craig B Reeder; Antonio M Padula Omuro; David Schiff; Brian O'Neill; Jose Pulido; Kurt A Jaeckle; Christian Grommes; Thomas E Witzig
Journal:  Blood       Date:  2018-09-27       Impact factor: 22.113

Review 5.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

6.  Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Authors:  Naval Daver; Aditi Shastri; Tapan Kadia; Kate Newberry; Naveen Pemmaraju; Elias Jabbour; Linghsa Zhou; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2014-07-06       Impact factor: 3.156

7.  Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  R F Schlenk; F Stegelmann; A Reiter; E Jost; N Gattermann; H Hebart; C Waller; A Hochhaus; U Platzbecker; P Schafhausen; I W Blau; W Verbeek; F H Heidel; M Werner; H Kreipe; V Teleanu; A Benner; H Döhner; M Grießhammer; K Döhner
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

Review 8.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

9.  Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

Authors:  Ruben A Mesa; Xiaopan Yao; Larry D Cripe; Chin Yang Li; Mark Litzow; Elisabeth Paietta; Jacob M Rowe; Ayalew Tefferi; Martin S Tallman
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

10.  Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.

Authors:  Yao Jiang; Jiang Wang; Darlene M Rozewski; Shamalatha Kolli; Chia-Hsien Wu; Ching-Shih Chen; Xiaoxia Yang; Craig C Hofmeister; John C Byrd; Amy J Johnson; Mitch A Phelps
Journal:  J Pharm Biomed Anal       Date:  2013-09-02       Impact factor: 3.935
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.